Companiesandmarkets.com

North America and Europe showing the highest number of cases within the pancreatic cancer market

Press Release   •   Jul 23, 2013 09:36 BST

The global pancreatic cancer market is projected to reach US$1.2 billion by 2015. Among all the regions, the United States has recorded the maximum number of pancreatic cancer cases, which are about 30,000 patients each year. The survival rate is less than 5 years which acts as a major hurdle for the growth of this market.

Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004).

The risk of developing pancreatic cancer is associated with increasing age, as more than 75% of pancreatic cancer patients are over the age of 60 years (SEER Cancer Statistics Review, 2012). Tobacco smoking is one of the most common risk factors for pancreatic cancer, as smokers have a two-fold increased risk of developing the disease compared with nonsmokers (Lowenfels and Maisonneuve, 2006).

The aggressive nature of pancreatic cancer and inadequate responses to the treatment acts as major obstacles in the treatment of such diseases.

Moreover, pancreatic cancer is diagnosed when it is in its advanced stage, leading to increase in mortality rate of the patients affected by such diseases. Only 15% to 12% of patients are diagnosed early enough thus making it possible to remove the tumour surgically.

The stages in pancreatic cancers include stage I, stage II, stage III and stage IV of which only stage I and stage II tumours can be removed surgically.

North America and Western Europe have the highest incidence of pancreatic cancer compared with the rest of the world. It has been forecast that the US and Germany will have the highest number of incident cases of pancreatic cancer in 2022, with 53,610 and 27,629 cases, respectively.

Eli Lilly's Gemzar (Gemcitabine) dominates the pancreatic cancer drug as it is presently the most advanced drug therapy recommended for stage III, IV or advanced stage treatments.

Eli Lilly's Gemzar (Gemcitabine) and Genentech/ OSI Pharmaceuticals/ Roche's Tarceva (Erlotinib) have captured the whole of the pancreatic cancer drug market as these are the only two approved therapies available for the treatment of pancreatic cancer. Of the two, Gemzar leads the market with about 55% share in the pancreatic cancer drugs market.

For more information on the pancreatic cancer market, see the latest research: Cancer Market Research

Follow us on Twitter @CandMResearch


Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.